DOCSLIB.ORG

Scientific Report 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2006 2007 2008 2009 2010 2011 2012 2013 2014 Tick tock toward 2025 toward tock Tick 2019 REPORT SCIENTIFIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Vall d'Hebron Institute of Oncology (VHIO) CELLEX CENTER C/Natzaret, 115 – 117 08035 Barcelona, Spain Tel. +34 93 254 34 50 www.vhio.net Direction: Amanda Wren Photography: Katherin Wermke Design: Parra estudio Vall d'Hebron Institute of Oncology (VHIO) | 2020 VHIO’s Scientific Report 2019: tick tock toward 2025 1 VHIO’s CELLEX CENTER: translation toward precision oncology 2 VHIO Scientific Report 2019 VHIO’s Scientific Report 2019: tick tock toward 2025 Index VHIO Scientific Report 2019 INTRODUCING VHIO 6 Foreword by VHIO’s Director 16 VHIO in 2019: Tick tock toward 2025 42 Scientific Productivity: research articles 43 Selection of some of the most relevant articles by VHIO researchers published in 2019 FROM THE PROGRAM DIRECTORS 52 Joaquín Arribas 54 Joan Seoane 56 Josep Tabernero PRECLINICAL & TRANSLATIONAL RESEARCH 64 Cellular Plasticity & Cancer Group 66 Chromatin Dynamics in Cancer Group 68 Experimental Therapeutics Group 70 Gene Expression & Cancer Group 72 Growth Factors Group 74 Mouse Models of Cancer Therapies Group 76 Stem Cells & Cancer Group 78 Tumor Biomarkers Group CLINICAL RESEARCH 82 Breast Cancer & Melanoma Group 84 Early Clinical Drug Development Group 86 Experimental Hematology Group 88 Gastrointestinal & Endocrine Tumors Group 90 Genitourinary, CNS Tumors, Sarcoma & Cancer of Unknown Primary Site Group 92 Gynecological Malignancies Group 94 Hereditary Cancer Genetics Group 96 Oncology Data Science (ODysSey) Group 98 Prostate Cancer Translational Research Group 100 Radiation Oncology Group 102 Radiomics Group 104 Sarcoma Translational Research Group 106 Thoracic Tumors & Head and Neck Cancer Group 108 Tumor Immunology & Immunotherapy Group CORE TECHNOLOGIES 112 Cancer Genomics Group 114 Molecular Oncology Group 116 Proteomics Group VHIO’s TRANSVERSAL CLINICAL TRIALS CORE SERVICES & UNITS 120 Clinical Trials Office 122 Research Unit for Molecular Therapy of Cancer (UITM) – ”la Caixa” 124 Clinical Research Oncology Nurses 126 Clinical Research Oncology Pharmacy Unit 128 VHIO's SCIENTIFIC COORDINATION AREA 130 Full listing of articles published by VHIO Investigators in 2019 148 Funding, Consortia & Accreditation 158 Extended version online: memorias.vhio.net/2019 PDF version: memorias.vhio.net/2019/SR-VHIO-2019.pdf JOSEP TABERNERO MARÍA ABAD JOAQUÍN ARRIBAS JUDITH BALMAÑA FRANCESC BOSCH VHIO'S Director FRANCESC CANALS JOAN CARLES RODRIGO DIENSTMANN ENRIQUETA FELIP ELENA GARRALDA JORDI GIRALT ALENA GROS TERESA MACARULLA JOAQUIN MATEO PAOLO G. NUCIFORO ANA OAKNIN HÉCTOR G. PALMER SANDRA PEIRÓ ÁNGELES PEÑUELAS RAQUEL PEREZ-LOPEZ MARÍA QUERALT GEMMA SALA CRISTINA SAURA JOAN SEOANE VIOLETA SERRA CÉSAR SERRANO LAURA SOUCEK JOSEP VILLANUEVA ANA VIVANCOS VHIO’s Scientific Report 2019: tick tock toward 2025 VHIO’s Scientific Report 2019: tick tock toward 2025 Championed by VHIO’s Director, Josep Tabernero, our Program Directors, Principal Investigators, and Heads of our Transversal Clinical Trials Core Services & Units, spearhead efforts aimed at solving cancer sooner. They lead their respective groups and teams to turn current obstacles in oncology into opportunities, and look ahead to the future to anticipate the challenges ahead. With the year 2025 rapidly approaching – the deadline to attain the World Health Organization’s 9 voluntary global targets for noncommunicable diseases – they continue to drive and accelerate research advancements that will ultimately contribute to meeting target 1 in cancer, namely, a 25% relative reduction in overall mortality from this disease. Introducing VHIO Foreword Organization’s (WHO) nine voluntary global targets for noncommunicable diseases (NCDs) and mental health. Target 1 promises a 25% relative reduction in overall mortality from cardiovascular diseases, cancer, diabetes, and chronic respiratory diseases. Progress in implementing the NCD Global Action plan is tracked by WHO’s Global monitoring framework on NCDs in order to monitor and report on the attainment Josep Tabernero of its nine global targets for Director, Vall d’Hebron Institute of Oncology (VHIO) NCDs by 2025. While COVID-19 is threatening our collective efforts to achieve this ambition in cancer, I believe that together VHIO in 2019: – along with the vital funding and necessary support networks tick tock toward 2025 firmly in place -- achieving this target might be within reach. One of the major European To mark the 25th anniversary this disease. As importantly, we funding programs, Horizon of Nature Medicine in 2019, the have learned from each other’s Europe, was announced in 2019 journal’s editorial team invited experiences, successes and failures and succeeds the European me and ten other experts in in order to avoid costly duplication Commission’s Horizon 2020 biomedicine to contribute to a and accelerate progress. funding program for research for special news feature by answering research and innovation. Within the question: What will shape the As this report goes to press, an (2) Horizon Europe’s framework, next 25 years of medical research? (1). article in The Lancet caught my attention. Sadly, the piece five key research and innovation As part of my response, I began by missions have been identified arguing that sweeping statements sheds a glaring light on the lack of collaboration and synergy to increase the effectiveness would be imprudent. Indeed, who of funding by pursuing clearly would have predicted that the between nations in tackling the COVID-19 catastrophe. Not only defined targets, ‘Missions’, future of biomedicine, research including cancer. The Cancer and the treatment and care of has this pandemic destroyed the foundations for protecting and Board, chaired by Walter Ricciardi patients suffering from serious (Rome, Italy), is flanked by its diseases such as cancer, would advancing health, but also it is threatening the aims set out in respective Assembly, on which I be compromised by the rapid and am truly honored to serve. The global explosion of COVID-19? the Millennium Development Goals and (since 2016) the Board and Assembly Members I strongly believe in joining Sustainable Development Goals. will collectively seek to deliver forces, nurturing and developing Simply put, the clock is ticking. on Mission’s goals. They are: partnerships, and exchanging data to ensure that more people live to overcome the many challenges This brings me back to the number without cancer, more cancer that hamper our efforts in solving 25. It is in fact the focus of this patients are diagnosed earlier, cancer sooner. Alongside like- year’s Scientific Report cover; a suffer less and have a better minded experts in oncology, VHIO time bar towards 2025. quality of life after treatment. we have forged numerous Here’s why: But it’s not just a matter of international consortia and multi- The year 2025 is the deadline strengthening and securing vital center studies that continue to to attain the World Health funding for cancer research of drive spectacular advances against 6 VHIO Scientific Report 2019 VHIO’s Scientific Report 2019: tick tock toward 2025 excellence. To deliver on these acknowledged by WHO’s Expert to highlight some of the many aforementioned ambitions, we Committee on Selection and important contributions must also seek to address many Use of Medicines in the 22nd made by our multidisciplinary other serious concerns. As an WHO Expert Committee on research teams in 2019, example, The European Society the 2019 Selection and Use of often in partnership with for Medical Oncology (ESMO) Medicines Report. Specifically, colleagues across the globe as -- for which I have had the the Committee stated that ‘all well as leading European and privilege to serve as President new EML cancer medicines, in international consortia. For an throughout the 2018-2019 term general, should have a score on additional pick of papers please -- has taken the lead in driving the ESMO-MCBS of A or B in the refer to From the Directors EU level action to tackle the curative setting and of 4 or 5 in the pages, 50-59. serious shortages of essential non-curative setting. These scores cancer medicines. These would support a medicine being Impactful cancer identified shortages obviously evaluated by the Expert Committee science and medicine have a direct impact on patient for inclusion in the EML through a at VHIO care across Europe. To ensure full application’. that this issue remains a top In 2019, VHIO researchers and priority on the EU policy agenda, The ESMO-MCBS major value- clinical scientists published ESMO collaborated with the based framework, launched an impressive 333 scientific European Parliament to organize in 2015, continues to undergo articles in leading journals as a cross-partisan event entitled finely-tuning in order to corresponding, senior, or co- Shortages of Inexpensive, Essential incorporate additional features authors (see full listing, pages Medicines: Calling for Tangible and criteria. Under constant 130-147). Many of these were Political Commitments in the EU, internal peer review, it has also published in the world’s most 09 April, Brussels (Belgium). recently been enriched with newly prestigious scientific and medical designed forms, a factsheet journals. During my ESMO Presidency, and booklet to facilitate the The Economist Intelligence Unit understanding of criteria, grading Here is just a small sample of and ESMO prepared a series of and
Recommended publications
  • Imatinib Does Not Support Its Use As an Antiviral Drug

    Imatinib Does Not Support Its Use As an Antiviral Drug

    bioRxiv preprint doi: https://doi.org/10.1101/2020.11.17.386904; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license. Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2 Franck Touret1 *, Jean-Sélim Driouich 1, Maxime Cochin1, Paul Rémi Petit1, Magali Gilles1, Karine Barthélémy1, Grégory Moureau1, Francois-Xavier Mahon2, Denis Malvy3,4 Caroline Solas5, Xavier de Lamballerie1, Antoine Nougairède1 1 Unité des Virus Émergents (UVE: Aix-Marseille University -IRD 190-Inserm 1207-IHU Méditerranée Infection), Marseille, France. 2 Cancer Center of Bordeaux, Institut Bergonié, INSERM U1218, University of Bordeaux, Bordeaux, France. 3 Department for Infectious and Tropical Diseases, University Hospital Center of Bordeaux, Bordeaux, France. 4 Inserm 1219, University of Bordeaux, Bordeaux, France. 5 APHM, Unité des Virus Émergents (UVE: Aix Marseille University IRD 190-Inserm 1207-IHU Méditerranée Infection), Laboratoire de Pharmacocinétique et Toxicologie, Hôpital La Timone, Marseille, France. *Correspondence: Franck Touret ([email protected]) Keywords: SARS-CoV-2; Covid-19; coronavirus; antivirals; tyrosine kinase inhibitor; Imatinib bioRxiv preprint doi: https://doi.org/10.1101/2020.11.17.386904; this version posted January 26, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-NC-ND 4.0 International license.
  • Targeting Fibrosis in the Duchenne Muscular Dystrophy Mice Model: an Uphill Battle

    Targeting Fibrosis in the Duchenne Muscular Dystrophy Mice Model: an Uphill Battle

    bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 Title: Targeting fibrosis in the Duchenne Muscular Dystrophy mice model: an uphill battle 2 Marine Theret1#, Marcela Low1#, Lucas Rempel1, Fang Fang Li1, Lin Wei Tung1, Osvaldo 3 Contreras3,4, Chih-Kai Chang1, Andrew Wu1, Hesham Soliman1,2, Fabio M.V. Rossi1 4 1School of Biomedical Engineering and the Biomedical Research Centre, Department of Medical 5 Genetics, 2222 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada 6 2Department of Pharmacology and Toxicology, Faculty of Pharmaceutical Sciences, Minia 7 University, Minia, Egypt 8 3Developmental and Stem Cell Biology Division, Victor Chang Cardiac Research Institute, 9 Darlinghurst, NSW, 2010, Australia 10 4Departamento de Biología Celular y Molecular and Center for Aging and Regeneration (CARE- 11 ChileUC), Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, 8331150 12 Santiago, Chile 13 # Denotes Co-first authorship 14 15 Keywords: drug screening, fibro/adipogenic progenitors, fibrosis, repair, skeletal muscle. 16 Correspondence to: 17 Marine Theret 18 School of Biomedical Engineering and the Biomedical Research Centre 19 University of British Columbia 20 2222 Health Sciences Mall, Vancouver, British Columbia 21 Tel: +1(604) 822 0441 fax: +1(604) 822 7815 22 Email: [email protected] 1 bioRxiv preprint doi: https://doi.org/10.1101/2021.01.20.427485; this version posted January 21, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder.
  • Identification of Candidate Repurposable Drugs to Combat COVID-19 Using a Signature-Based Approach

    Identification of Candidate Repurposable Drugs to Combat COVID-19 Using a Signature-Based Approach

    www.nature.com/scientificreports OPEN Identifcation of candidate repurposable drugs to combat COVID‑19 using a signature‑based approach Sinead M. O’Donovan1,10, Ali Imami1,10, Hunter Eby1, Nicholas D. Henkel1, Justin Fortune Creeden1, Sophie Asah1, Xiaolu Zhang1, Xiaojun Wu1, Rawan Alnafsah1, R. Travis Taylor2, James Reigle3,4, Alexander Thorman6, Behrouz Shamsaei4, Jarek Meller4,5,6,7,8 & Robert E. McCullumsmith1,9* The COVID‑19 pandemic caused by the novel SARS‑CoV‑2 is more contagious than other coronaviruses and has higher rates of mortality than infuenza. Identifcation of efective therapeutics is a crucial tool to treat those infected with SARS‑CoV‑2 and limit the spread of this novel disease globally. We deployed a bioinformatics workfow to identify candidate drugs for the treatment of COVID‑19. Using an “omics” repository, the Library of Integrated Network‑Based Cellular Signatures (LINCS), we simultaneously probed transcriptomic signatures of putative COVID‑19 drugs and publicly available SARS‑CoV‑2 infected cell lines to identify novel therapeutics. We identifed a shortlist of 20 candidate drugs: 8 are already under trial for the treatment of COVID‑19, the remaining 12 have antiviral properties and 6 have antiviral efcacy against coronaviruses specifcally, in vitro. All candidate drugs are either FDA approved or are under investigation. Our candidate drug fndings are discordant with (i.e., reverse) SARS‑CoV‑2 transcriptome signatures generated in vitro, and a subset are also identifed in transcriptome signatures generated from COVID‑19 patient samples, like the MEK inhibitor selumetinib. Overall, our fndings provide additional support for drugs that are already being explored as therapeutic agents for the treatment of COVID‑19 and identify promising novel targets that are worthy of further investigation.
  • Dossier 53Ralli Comprimit Com

    Dossier 53Ralli Comprimit Com

    PRESENTACIÓ / PRESENTACIÓN El Ral·li Internacional de la Noguera Pallaresa és El Rally Internacional de la Noguera Pallaresa es un esdeveniment amb mig segle d’història que un evento con medio siglo de historia que acoge acull diverses competicions i activitats distintas competiciones y actividades relacionades amb el piragüisme i els esports relacionadas con el piragüismo y los deportes d’aigües braves. de aguas bravas. Aquest tipus d’activitats s’introduïren a l’Estat a Este tipo de actividades se introdujeron en el través de la Noguera Pallaresa, cosa que va Estado a través del Noguera Pallaresa, cosa que contribuir al desenvolupament turístic de la contribuyó en el desarrollo turístico de la comarca i a convertir el Ral·li en una de les comarca y a convertir el Rally en una de las competicions de piragüisme d’aigües braves competiciones de piragüismo de aguas bravas més antigues de l’Estat (des de 1964). más antiguas del Estado (desde 1964). El Ral·li s’organitza conjuntament entre l'A.E. El Ral·li se organiza conjuntamente entre l’A.E. Pallars i l'Ajuntament de Sort. L'A.E. Pallars és Pallars y el Ayuntamiento de Sort. L’A.E. Pallars un club esportiu amb cinquanta anys d’història es un club deportivo con cincuenta años de arrelat al poble de Sort, amb una llarga tradició historia arraigado al pueblo de Sort, con una en el desenvolupament d’aquest tipus larga tradición en el desarrollo de este tipo de d’esdeveniments. En aquest cas, l’A.E. Pallars eventos. En este caso, l’A.E.
  • La Inventariació Dels Arxius Municipals De Les Comarques De La Noguera, La

    La Inventariació Dels Arxius Municipals De Les Comarques De La Noguera, La

    Revista Catalana d'Arxivística LLIGALiyS (1992) LA INVENTARIACIÓ DELS ARXIUS MUNICIPALS DE LES COMARQUES DE LA NOGUERA, LA SEGARRA I L'URGELL Joan Farré i Viladrich (Arxiu Històric Comarcal de Balaguer) Gener Gonzalvo i Bou (Arxiu Històric Comarcal de Tàrrega) Dolors Montagut i Balcells (Arxiu Històric Comarcal de Cervera) Introducció boració dels inventaris dels arxius munici- pals s'inicià simultàniament a les comarques Amb la creació de la Xarxa d'Arxius de l'Urgell, la Noguera, l'Alt UrgeU, el Històrics Comarcals (Llei d'Arxius de Cata- Segrià i la Segarra. Una part dels arxius lunya 6/1985, de 26 d'abril), i el Decret municipals del Pla d'Urgell foren visitats i que en regula la seva organització (Decret inventariats des de Balaguer, Lleida i Tàr- d'Organització de la Xarxa d'Arxius Histò- rega, ja que aleshores no estava creada ofi- rics Comarcals, 110/1988, de 5 de cialment la nova comarca. maig) ^ s'atribueix a aquests arxius la El projecte va rebre un important recol- tutela, protecció, conservació i difusió del zament per part de la Diputació de Lleida, patrimoni documental de la comarca. Es en institució que es va fer càrrec de la contrac- aquest context on hem d'emmarcar el pro- tació de dos llicenciats en història per a cada grama de treball establert i coordinat pel arxiu comarcal (AHC de Balaguer, AHC de Servei d'Arxius de la Generalitat de Cata- la Seu d'UrgeU, AHC de Tàrrega, AHC de lunya, d'inventariació dels fons documen- Cervera, i Arxiu Històric de Lleida). La tals municipals de les comarques de Lleida, mateixa institució va dotar els arxius comar- dins un projecte més ampli d'inventari dels cals d'equips informàtics que han permès arxius municipals de Catalunya^.
  • Mast Cell Leukemia

    Mast Cell Leukemia

    European Journal of Haematology ORIGINAL ARTICLE Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor Sophie Georgin-Lavialle1,2,3, Ludovic Lhermitte2,4,*, Felipe Suarez5,*, Ying Yang6,7,Se´ bastien Letard6,7, Katia Hanssens6,7, Fre´ de´ ric Feger2, Ame´ de´ e Renand2, Chantal Brouze4, Danielle Canioni1,8, Vahid Asnafi4, Marie-Olivia Chandesris1,5, Achille Aouba5, Paul Gineste9, Elizabeth Macintyre4, Colin D. Mansfield9, Alain Moussy9, Yves Lepelletier2, Patrice Dubreuil6,7, , Olivier Hermine1,2,5, 1Centre de Re´ fe´ rence des Mastocytoses, Faculte´ de Me´ decine et AP-HP Necker-Enfants Malades; 2CNRS UMR 8147, Hoˆ pital Necker-Enfants malades; 3Service de Me´ decine Interne, Hoˆ pital Europe´ en Georges Pompidou, Universite´ Paris Descartes, Paris Sorbonne Cite´ , Assistance Publique-Hoˆ pitaux de Paris; 4Laboratoire d’he´ matologie Biologique et UMR CNRS 8147, Universite´ Paris Descartes, Paris Sorbonne Cite´ , Faculte´ de Me´ decine et AP-HP Necker-Enfants Malades; 5Service d’He´ matologie Adultes, Universite´ Paris Descartes, Paris Sorbonne Cite´ , Faculte´ de Me´ decine et AP-HP Necker-Enfants Malades, Paris; 6INSERM U891, Centre de Recherche en Cance´ rologie de Marseille, Laboratoire de Signalisation, He´ matopoı¨e` se et Me´ canisme de l’Oncogene` se, Centre de re´ fe´ rence des Mastocytoses; 7Institut Paoli-Calmettes, Marseille, France; Univ Me´ diterrane´ e, Marseille; 8Laboratoire d’anatomopathologie, Universite´ Paris Descartes, Paris Sorbonne Cite´ , Faculte´ de Me´ decine et AP-HP Necker-Enfants Malades; 9AB Science, 3 avenue Georges V, Paris, France Abstract Objective: Most patients with systemic mastocytosis bear mutations in the tyrosine kinase receptor gene c-Kit.
  • The-Royal-Birthday-Calendar-Kopie-3

    The-Royal-Birthday-Calendar-Kopie-3

    THE ROYAL PAGES.COM The Royal Birthday European Royal Houses C a l e n d a r January February March April 05 - King Juan Carlos I. of Spain (1938) 01 - Princess Stéphanie of Monaco (1965) 01 - Vice Admiral Sir Timothy Laurence 10 - Princess Ariane of the Netherlands - Prince Vincent and Princess (1955) (2007) 08 05 - Crown Princess Mary of Denmark 15 - King Philippe of the Belgians (1960) Josephine of Denmark (2011) (1972) 02 - Prince Oscar of Sweden (2016) 09 - Catherine, Duchess of Cambridge 16 - Queen Margarethe II. of Denmark 06 - Princess Marie of Denmark (1976) 09 - Princess Adrienne of Sweden (2018) (1982) (1940) 14 - Prince Hans-Adam II. of 16 - Grand Duke Henri of Luxembourg 20 - Sophie, Countess of Wessex (1965) 10 - Prince Edward, Earl of Wessex (1964) Liechtenstein (1945) (1955) 20 - Queen Mathilde of the Belgians (1973) 19 - Prince Andrew, Duke of York (1960) 14 - Prince Albert II. of Monaco (1958) 16 - Princess Eleonore of the Belgians (2008) 19 - Prince Alexander of Sweden (2016) 21 - Princess Ingrid Alexandra of Norway 20 - Princess Leonore of Sweden (2014) 22 - Grand Duchess Maria Teresa of (2004) 21 - Queen Elizabeth II. of the UK (1926) 21 - King Harald V. of Norway (1937) Luxembourg (1956) 23 - Princess Caroline of Hanover (1957) 21 - Princess Isabella of Denmark (2007) 23 - Princess Estelle of Sweden (2012) 23 - Princess Eugenie of York (1990) 23 - Prince Louis of Cambridge (2018) 25 - Princess Charlène of Monaco (1978) 26 - Prince Ernst August V. of Hanover 27 - King Willem of the Netherlands (1967) 30 - King Felipe VI. of Spain (1968) (1954) 29 - Infanta Sofia of Spain (2007) 31 - Princess Beatrix of the Netherlands 30 - King Carl XVI Gustaf of Sweden (1946) (1938) May June July August 02 - Princess Charlotte of Cambridge (2015) 05 - Princess Astrid of the Belgians (1962) 04 - Queen Sonja of Norway (1937) 03 - Prince Louis of Luxembourg (1986) 04 - Archie Harrison Mountbatten-Windsor 06 - King Albert II.
  • Regional Aid Map 2007-2013 EN

    Regional Aid Map 2007-2013 EN

    EUROPEAN COMMISSION Competition DG Brussels, C(2006) Subject: State aid N 626/2006 – Spain Regional aid map 2007-2013 Sir, 1. PROCEDURE 1. On 21 December 2005, the Commission adopted the Guidelines on National Regional Aid for 2007-20131 (hereinafter “RAG”). 2. In accordance with paragraph 100 of the RAG, each Member State should notify to the Commission, following the procedure of Article 88(3) of the EC Treaty, a single regional aid map covering its entire national territory which will apply for the period 2007-2013. In accordance with paragraph 101 of the RAG, the approved regional aid map is to be published in the Official Journal of the European Union and will be considered as an integral part of the RAG. 3. On 13 March 2006, a pre-notification meeting between the Spanish authorities and the Commission's services took place. 4. By letter of 19 September 2006, registered at the Commission on the same day with the reference number A/37353, Spain notified its regional aid map for the period from 1 January 2007 to 31 December 2013. 5. By letter of 23 October 2006 (reference number D/59110) the Commission requested from the Spanish authorities additional information. 6. By letter of 15 November 2006, registered at the Commission with the reference number A/39174, the Spanish authorities submitted additional information. 1 OJ C 54, 4.3.2006, p. 13. 2. DESCRIPTION 2.1. Main characteristics of the Spanish Regional aid map 7. Articles 40(1) and 138(1) of the Spanish Constitution establish the obligation of the public authorities to look after a fair distribution of the wealth among and a balanced development of the various parts of the Spanish territory.
  • Un Aspecte Gairebé Desconegut Del Patrimoni Monumental De L'urgell

    Un Aspecte Gairebé Desconegut Del Patrimoni Monumental De L'urgell

    U N ASPECTE GAIREBÉ DESCONEGUT DEL PATRIMONI MONUMENTAL DE L’URGELL: ELS MOLINS DE VENT Joan Ramon González Pérez Daniel Rubio Ruiz Josep Ignasi Rodríguez Duque UN ASPECTE GAIREBÉ DESCONEGUT DEL PATRIMONI MONUMENTAL DE L’URGELL: ELS MOLINS DE VENT Comunicació Introducció subtroncocònica que si bé eren situades en llocs dominants, tenien una sèrie de peculia- Joan Ramon La utilització de l’energia eòlica és un fet nor- ritats que les diferenciava de les torres de guai- González Pérez mal al llarg de la història humana, sobretot ta. Per una banda l’entrada es trobava a peu quan les societats assoleixen un grau de tec- pla, els murs tenien un gruix inferior al metre i Daniel nologia suficient. No obstant tots tenim una la qualitat de la pedra i del morter no aconse- Rubio Ruiz sèrie d’arquetipus que ens fan associar el molí guien els acabats de les torres del segle XI; de vent amb un determinat paisatge; que va per una altra banda encara que eren en llocs Josep Ignasi des de la mateixa Mancha a les costes llevan- enlairats, de vegades corresponien al mig Rodríguez Duque tines de la Mediterrània i d’una manera espe- d’una suau i ampla carena i quan eren en es- cial a les Balears. L’existència dels molins de perons mai tenien fossat per la part més Servei d’Arqueologia de vent porta associada dues característiques fí- accesible. El fet de ser conegudes popular- la Fundació Pública siques fonamentals: per una banda un espai ment com “torres dels moros” no ajudava mas- Institut d’Estudis ampli on bufin vents amb suficient força i fre- sa a la seva correcta interpretació i això expli- IIerdencs de la Diputació de Lleida qüència, i per un altre una manca de lleres d’ai- caria que foren publicades com a fortifica- gua adequades per a l’aprofitament de l’energia cions en excel·lents treballs de caràcter hidràulica derivada.
  • Andreu Dameson

    Andreu Dameson

    Andreu Dameson i Aspa (La Garriga, 1897 - Buenos Aires, 1968) personatge inquiet ANDREU i seductor, va viure a cavall de la Catalunya natal i l’Argentina d’adopció, deixant en DAMESON ambdós països una memorable petjada tant professional com vital. El seu compromís d’esquerres, republicà i catalanista el portaren a un exili del que GENI DE LA no pogué tornar ja mai més i ha estat la causa de l’injustifi cat oblit de la seva impor- CARICATURA tant obra, al qual aquest llibre vol posar-hi fi . Dameson, dibuixant, pintor, il·lustrador, periodista, escriptor... es defi nia, per da- munt de tot, com a caricaturista. Sens dubte, en fou un dels millors del segle XX. LLUÍS SOLÀ I DACHS JAUME CAPDEVILA Lluís Solà i Dachs (Barcelona, 1932) Jaume Capdevila i Herrero «Kap» GENI DE LA CARICATURA Enginyer tèxtil. Ha estudiat la premsa humorística il·lustrada (Berga, 1974) catalana i ha publicat antologies dels setmanaris més Llicenciat en Belles Arts per la UB. populars. Les seves obres principals són Dibuixant d’humor, il·lustrador L’humor català (3 vols.), El Be Negre (2 vols.), i caricaturista. Ha publicat, Història dels diaris en català, L’humor culer entre d’altres, a La Vanguardia, (amb el dibuixant Cesc), La caricatura política i social a Mundo Deportivo i El Triangle. Catalunya i Papitu i les publicacions erótico-sicalíptiques Ha estudiat destacats ninotaires del seu temps, entre altres. catalans com Lluís Bagaria Ha dirigit i col·laborat en diverses exposicions o Tísner. El 2009 va rebre i ha publicat nombrosos articles en diaris, el Premi Internacional ANDREU DAMESON ANDREU DAMESON revistes i catàlegs.
  • Factors Influencing Clinical Trial Site Selection in Europe

    Factors Influencing Clinical Trial Site Selection in Europe

    BMJ Open: first published as 10.1136/bmjopen-2013-002957 on 15 November 2013. Downloaded from Open Access Research Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study) Marta Gehring,1 Rod S Taylor,2 Marie Mellody,3 Brigitte Casteels,4 Angela Piazzi,3 Gianfranco Gensini,5 Giuseppe Ambrosio6 To cite: Gehring M, ABSTRACT et al Strengths and limitations of this study Taylor RS, Mellody M, . Objectives: Applications to run clinical trials in Factors influencing clinical Europe fell 25% between 2007 and 2011. Costs, speed ▪ trial site selection in Europe: We provide systematic evidence across a large of approvals and shortcomings of European Clinical the Survey of Attitudes sample of expert professionals indicating that towards Trial sites in Europe Trial Directive are commonly invoked to explain this fostering competitiveness of European clinical (the SAT-EU Study). BMJ unsatisfactory performance. However, no hard evidence research may not require additional government Open 2013;3:e002957. is available on the actual weight of these factors or has spending/incentives. Carefully crafted harmonisa- doi:10.1136/bmjopen-2013- it been previously investigated whether other criteria tion of approvals, greater visibility of centres of 002957 may also impact clinical trial site selection. excellence via disease networks/the web, and Design: The Survey of Attitudes towards Trial sites in reduction of ‘hidden’ costs are more likely to ▸ Prepublication history for Europe (SAT-EU Study) was an anonymous, cross- boost competitiveness of European clinical this paper is available online. sectional web-based survey that systematically research.
  • Mississippi River Trail Groundbreaking Will Include a 10 Ft

    Mississippi River Trail Groundbreaking Will Include a 10 Ft

    The St.Remembering Bernard Our Past, Building a Better Future News www.thestbernardnews.com Wednesday, July 4, 2018 Volume 52, Issue 28 "Therefore, if anyone is in Christ, he is a new creation; the old has gone, the new has come!" – 2 Cor. 5:17 (NIV) Mississippi River Trail Groundbreaking will include a 10 ft. wide asphalt includes a trailhead and access path on top of the Mississippi ramp that will be located on River levee and a handicapped property donated by the Meraux accessible ramp and trailhead Foundation. near the Violet Canal terminus. Construction will be per- This $1.3 million project is formed by Barber Construction funded by a grant from the U.S. based on the trail design devel- Department of Transportation, oped by Evans-Graves Engi- Federal Highway Administration neers, Inc. Additional engineer- which is administered in Loui- ing services for the project will siana by the state Department be provided by Digital Engineer- of Transportation and Devel- ing. Construction on this phase opment. Planning assistance is expected to be completed by was provided by the Regional December, 2018. Planning Com- mission for Jef- ferson, Orleans, Plaquemines, Mississippi River Trail Groundbreaking. Photos by Lenor Duplessis. St. Bernard, St. Charles, St. St. Bernard Parish Govern- fices in Violet. John the Bap- ment held a groundbreaking This phase of the trail extends tist, St. Tamma- for construction of the Missis- from the east side of Valero Re- ny and Tangipa- sippi River Trail behind Lake finery in Meraux to the Violet hoa Parishes. Borgne Basin Levee District Of- Canal in Violet.